Oxygen Compound Of Arsenic Patents (Class 424/623)
  • Patent number: 10238631
    Abstract: A new class of sesquiterpene derivative useful for treating cancerous and inflammatory diseases are disclosed. These deoxyelephantopin derivatives are effective in suppressing proliferation, migration, mobility, invasion, growth, and/or metastasis of cancer cells in a patient, or useful for enhancing an anti-proliferative effect of another anti-cancer drug on cancer cells when treating a patient, or for sensitizing and/or enhancing an anti-cancer effect of a gluthathione synthesis blocker on inhibition of triple negative breast cancer cell activity, or for treatment and/or prophylaxis of lipopolysaccharide-stimulated inflammatory response in a patient, or for all of the above. Also disclosed are methods of preparing the deoxyelephantopin derivatives.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 26, 2019
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Kuo-Hsiung Lee, Kyoko Nakagawa-Goto, Jia-Hua Feng, Jo-Yu Chen, Wai-Leng Lee, Yu-Ting Cheng, Jing-Ying Huang
  • Patent number: 10226517
    Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 12, 2019
    Assignee: Alma Bio Therapeutics
    Inventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
  • Patent number: 10149887
    Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells, and combinations of T cell activating agents and/or an immune checkpoint inhibitors with and without peptides and peptidimimetics. The invention compounds and combinations can be used to inhibit cell growth, such as treat a tumor or cancer.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 11, 2018
    Assignee: CanBas Co., Ltd.
    Inventor: Takumi Kawabe
  • Patent number: 10092595
    Abstract: Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: October 9, 2018
    Assignee: The University of Hong Kong
    Inventor: Yok-Lam Kwong
  • Patent number: 9974843
    Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: May 22, 2018
    Assignee: Alma Bio Therapeutics
    Inventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
  • Patent number: 9801851
    Abstract: In one aspect, the invention relates to compositions comprising BCR-ABL tyrosine kinase inhibitors and artemisinin analogs, derivatives thereof, or related compounds, which are useful as in treating Philadelphia chromosome positive leukemias; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with BCR-ABL dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: October 31, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Harpreet Singh, Richard T. Williams, Kiplin R. Guy
  • Patent number: 9730928
    Abstract: In one aspect, the invention relates to triazol-1-ol compounds, analogs thereof, compositions comprising same, and methods of using same, alone or in combination with other agents, to reactivate latent retroviruses, and more particularly to reactivate latent HIV-1. Such compounds, compositions, and methods can be used, for example, in connection with diagnosing and/or treating a retrovirus, and more specifically HIV-1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 15, 2017
    Assignee: Univeristy of Utah Research Foundation
    Inventors: Vincente Planelles, Alberto Bosque-Pardos, Chris M. Ireland, Ryan Van Wagoner, Mary Kay Harper-Ireland, John Alan Maschek
  • Patent number: 9440988
    Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: September 13, 2016
    Assignee: John Hopkins University School of Medicine
    Inventors: Philip A. Beachy, James K. Chen, Anssi Jussi Nikolai Taipale
  • Publication number: 20150111730
    Abstract: A pesticidal composition comprises a compound of formula I or any agriculturally acceptable salt thereof, wherein R1, R2, R4, R5, R6, R7, Z, Q, and Y are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests, or to an area to control pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Noormohamed M. Niyaz, Ann M. Buysse, David A. Demeter, Negar Garizi, Ricky Hunter, Daniel Knueppel, Paul R. LePlae, Christian T. Lowe, Akshay Patny, Tony K. Trullinger, Martin J. Walsh, Yu Zhang
  • Publication number: 20150111731
    Abstract: A pesticidal composition comprises one or more of the following compounds: 3-(thiazol-2-yl)pyridine 1-oxide compound of formula I or II, or N-(4-chloro-2-(pyridin-3-yl)thiazol-5-yl)-3-(methylthio)propanamide compound (C3), or any agriculturally acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and Q, are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Negar Garizi, Martin J. Walsh, Ann M. Buysse, Daniel Knueppel, Asako Kubota, Noormohamed M. Niyaz, Yu Zhang, Ricky Hunter, Tony K. Trullinger
  • Publication number: 20150111733
    Abstract: A pesticidal composition comprises at least one compound selected from a 1-(3-pyridyl-N-oxide)pyrazole compound of formula I, II, or III, or any agriculturally acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R12, R13, Y, and Q, are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Martin J. Walsh, Daniel Knueppel, Noormohamed M. Niyaz, Ann M. Buysse, Negar Garizi, Asako Kubota, Yu Zhang, Ricky Hunter, Tony K. Trullinger
  • Publication number: 20150110713
    Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Anthony Manganaro, Karen Rockwell
  • Publication number: 20150111732
    Abstract: A pesticidal composition comprises a 3-(1H-pyrazol)pyridine compound of formula I or any agriculturally acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, R12, x, n, and Q are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Martin J. Walsh, Ann M. Buysse, Asako Kubota, Noormohamed M. Niyaz, Yu Zhang, Ricky Hunter, Tony K. Trullinger
  • Publication number: 20150111734
    Abstract: A pesticidal composition comprises at least one compounds selected from a compound of formula, or any agriculturally acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, Q, Z, L, La, and x are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Yu Zhang, Asako Kubota, Noormohamed M. Niyaz, Thomas Barton, Tony K. Trullinger, Christian T. Lowe, Paul R. LePlae, Ann M. Buysse, Martin J. Walsh, Negar Garizi, Ricky Hunter, Daniel Knueppel
  • Patent number: 8999289
    Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: April 7, 2015
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty
  • Publication number: 20150024065
    Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.
    Type: Application
    Filed: June 20, 2014
    Publication date: January 22, 2015
    Inventors: Andrea Savarino, Marina Lusic
  • Publication number: 20150017259
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: August 21, 2014
    Publication date: January 15, 2015
    Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
  • Publication number: 20150004157
    Abstract: The present invention relates to a therapeutic comprising an osteopontin isoform a (“OPNa”) inhibitor where the OPNa inhibitor blocks activity of extracellular OPNa exon 4. The OPNa inhibitor is selected from the group consisting of (i) an exon-4 specific antibody or binding portion thereof; (ii) a peptide mimic of OPNa exon 4 or a fragment thereof; (iii) a nucleic acid aptamer that specifically binds to OPNa exon 4 or a fragment thereof; and (iv) a peptide inhibitor that binds to OPNa exon 4 or a fragment thereof. The present invention also relates to methods of inhibiting tumor growth and/or metastasis in a subject, treating a subject with chemotherapeutic resistance, and methods of increasing tumor cell sensitivity to a cancer therapeutic by administering an OPNa inhibitor according to the present invention.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 1, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Harvey I. Pass, Jessica S. Donington, Chandra M. Goparaju
  • Publication number: 20140370119
    Abstract: An arsenic compound solution, and an albumin nanoparticle and a lyophilized preparation prepared using same and entrapping an arsenic compound. The arsenic compound solution is prepared using the following method: adding As2O3 powder in sterile deionized water to obtain a suspension, 6 to 25 mg of As2O3 powder being added in every mL of sterile deionized water; dripping an NaOH solution to the obtained suspension until the powder is fully dissolved and adjusting the pH of the solution to 7.5 to 9, and making the concentration of the obtained arsenic compound solution be 5 to 20 mg/mL in terms of the added As2O3. The albumin nanoparticle is prepared by mixing an albumin solution and the arsenic solution and the arsenic solution with the mass ratio of the added As2O3 in arsenic compound solution to the albumin ranging from 1:5 to 1:20 and using a method of solvent removing and physical curing.
    Type: Application
    Filed: January 5, 2013
    Publication date: December 18, 2014
    Applicant: ZHEJIANG CHINESE MEDICAL UNIVERSITY
    Inventors: Lanhua Lou, Yongsheng Fan, Chengping Wen
  • Patent number: 8911792
    Abstract: Disclosed herein is a composition concentrate that is suitable for treating wood upon dilution with water in a weight ratio of concentrate to water of between 1:10 and 1:100. The concentrate contains copper ammonium cations, zinc ammonium cations, arsenate and/or hydrogen arsenate anions; carbonate and/or bicarbonate anions, ammonia and water, wherein the total amount of copper and zinc is from 17% to about 22% by weight based on the total volume of the concentrate. Also disclosed is a process for producing ammoniacal copper zinc arsenate concentrate.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: December 16, 2014
    Assignee: Arch Wood Protection, Inc.
    Inventors: Jayesh P. Patel, Gloriana Kuswanto
  • Patent number: 8906422
    Abstract: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. The composition can also contain one or more pharmaceutically acceptable carriers and/or excipients.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: December 9, 2014
    Assignee: The University of Hong Kong
    Inventor: Yok-Lam Kwong
  • Patent number: 8900565
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • Publication number: 20140296068
    Abstract: This document discloses molecules having the following formula (Formula One) and processes related thereto.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 2, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Negar Garizi, Tony K. Trullinger, Ricky Hunter, Yu Zhang, Noormohamed M. Niyaz, Daniel Knueppel, Christian T. Lowe, Ann M. Buysse
  • Publication number: 20140271729
    Abstract: This invention relates to a composition, and methods of administration and treatment comprising a homeopathic preparation of an effective amount of Spermine and/or Spermidine that improves hormone imbalances in males and females. The purpose of the invention is to provide a homeopathic treatment comprising Spermine and/or Spermidine that demonstrates improvement in energy, sleep, sexual function, relief of prostrate symptoms, lighter and shorter hot flush symptoms, stamina, weight loss, and the overall mood and stress of a patient.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Apotheca, Inc.
    Inventor: Jesse Rettig
  • Publication number: 20140242190
    Abstract: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analogue thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: Academia Sinica
    Inventors: Lie-Fen SHYUR, Wen-Wan CHAO, Ya-Wen CHENG
  • Publication number: 20140220154
    Abstract: What is described is a method of preventing or treating heterotopic ossification, vascular calcification, and pathologic mineralization, comprising administering an drug, wherein the drug is an antagonist of the Hedgehog (Hh) pathway. For example the antagonist consists of arsenic trioxide, sodium arsenite, phenylarsine, GANT-58, GANT-61, zerumbone vismodegib (GDC-0449, Genentech), bevacizumab, gemcitabine, nab-paclitaxel, FOLFIR, FOLFOX, RO4929097, cixutumumab, cisplatin, etoposide, LDAC, decitabine, daunorubicin, cytarabin, rosiglitazone, goserelin, leuprolide, capecitabine, fluorouracil, leucovorin, oxaliplatin, irinotecan, diclofenac, BMS-833923 (XL139), IPI-926—Infinity Pharmaceuticals, Inc., LDE225, LEQ506—Novartis Pharmaceuticals, TAK-441 Millennium Pharmaceuticals, Inc., and PF-04449913—Pfizer, alone or in combination therapy.
    Type: Application
    Filed: June 28, 2012
    Publication date: August 7, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Jean Regard, Yingzi Yang
  • Patent number: 8784797
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 22, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Brirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Patent number: 8784899
    Abstract: The present invention relates to compositions comprising a vitamin E analog and an arsenic compound for treating hyperproliferative cells disorders such as cancer. The composition of the invention potentiates arsenic toxicity towards cancer cells and can also prevent arsenic-mediated toxicity of non-cancerous cells.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: July 22, 2014
    Assignee: Samuel Waxman Cancer Research Foundation
    Inventors: Wilson H. Miller, Zuanel Diaz Heredia, Hyman M. Schipper, Koren K. Mann
  • Patent number: 8754121
    Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: June 17, 2014
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
  • Publication number: 20140106003
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Application
    Filed: August 6, 2013
    Publication date: April 17, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Publication number: 20140072529
    Abstract: The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agent
    Type: Application
    Filed: March 29, 2012
    Publication date: March 13, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
  • Publication number: 20140023642
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 31, 2012
    Publication date: January 23, 2014
    Applicant: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • Publication number: 20140017336
    Abstract: It has now been discovered that arsenic induces herpes viruses latent in infected cells to reactivate to the lytic stage. Herpes viruses in the lytic stage activate anti-herpes virus anti viral agents. Co-administration of arsenic compounds and anti-herpes viral agents to a population of cells infected with a herpes virus results in the death of the cells and inhibits proliferation of the virus. The invention is therefore useful for reducing a subject's population of cells infected with herpes viruses, particularly Epstein-Barr virus.
    Type: Application
    Filed: April 6, 2012
    Publication date: January 16, 2014
    Applicant: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Mark D. Sides, Joseph A. Lasky
  • Publication number: 20130344083
    Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.
    Type: Application
    Filed: March 14, 2013
    Publication date: December 26, 2013
    Inventors: C. Wilson Xu, Yasuyo Urasaki
  • Patent number: 8591943
    Abstract: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongqi Deng, Binyuan Sun, Hongbo Zeng, Matthew Richards, Gerald W. Shipps, Jr., Cliff C. Cheng, Yinyan Zhao, Andrew McRiner, Zhaoyang Meng, Yang Nan, Mehul F. Patel, Iwona E. Wrona, Panduranga Adulla Reddy, Brian M. Eklov, Shuyi Tang, Duan Liu, Amit K. Mandal, Lianyun Zhao, M. Arshad Siddiqui
  • Publication number: 20130309319
    Abstract: The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (As2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: November 21, 2013
    Applicant: PANAPHIX INC.
    Inventors: Michael HWANG, Yong Jin YANG
  • Publication number: 20130287791
    Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Inventor: C. Wilson Xu
  • Publication number: 20130230542
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
  • Publication number: 20130224310
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.
    Type: Application
    Filed: June 5, 2012
    Publication date: August 29, 2013
    Applicant: Emory University
    Inventors: Harish C. Joshi, Ritu Aneja, Surya N. Vangapandu
  • Patent number: 8497300
    Abstract: The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: July 30, 2013
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Kmar Chelbi Alix, Pedro Bobe
  • Publication number: 20130189373
    Abstract: A pharmaceutical composition for treating cancer, in particular drug resistant cancer, comprising an effective amount of bifunctional alkylating agent, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 27, 2010
    Publication date: July 25, 2013
    Applicant: Academai Sinica
    Inventors: Te-Chang Lee, Tsann-Long Su, Tang-Chiao Chiou
  • Publication number: 20130183388
    Abstract: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 18, 2013
    Applicant: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventor: Lankenau Institute for Medical Research
  • Publication number: 20130156865
    Abstract: Certain PDE-4 inhibitors are useful for the treatment of myeloid and linphoyd malignancies.
    Type: Application
    Filed: December 14, 2012
    Publication date: June 20, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Chiesi Farmaceutici S.p.A.
  • Publication number: 20130156727
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: November 21, 2012
    Publication date: June 20, 2013
    Applicant: Pharmacyclics, Inc.
    Inventor: Pharmacyclics, Inc.
  • Publication number: 20130089622
    Abstract: This document discloses molecules having the following formula (“Formula I”):
    Type: Application
    Filed: November 14, 2012
    Publication date: April 11, 2013
    Applicant: Dow AgroSciences LLC
    Inventor: Dow AgroSciences LLC
  • Patent number: 8394422
    Abstract: The invention relates to a method for treating and/or preventing autoimmune and/or inflammatory diseases, including the graft-versus-host disease, comprising administering to a patient in need thereof, a therapeutically effective amount of an arsenic compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: March 12, 2013
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Kmar Chelbi Alix, Pedro Bobé
  • Publication number: 20130039904
    Abstract: The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: Where ring A, ring B or/and ring C is 4-10 membered saturated or/and unsaturated aliphatic ring aliphatic heterocycle or aryl heterocycle. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted substituent of glycosyl, multi-hydroxyl, amino acid, acyloxy, phosphoric acid oxy, sulfonyloxy, alkoxy, aryloxy, heterocyclic oxy, thiol, aliphatic or cyclic group containing oxygen, sulfur, nitrogen or phosphorus, one of the substituents or combinations thereof. The present invention has antitumor activity management, antiviral, antibacterial and antifungal activity management, as anti-tumor, anti-viral, immune, antibacterial and antifungal agents, with other known anti-tumor, anti-viral, immune, together with the application of antibacterial and antifungal.
    Type: Application
    Filed: August 2, 2010
    Publication date: February 14, 2013
    Applicant: Liaoning Lifeng Scientific & Technology Development Company Ltd.
    Inventor: Lifeng Xu
  • Publication number: 20120321591
    Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 20, 2012
    Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
  • Publication number: 20120294955
    Abstract: A method of inhibiting, preventing, or reducing damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 22, 2012
    Inventor: Zhi-Min Yuan
  • Publication number: 20120251628
    Abstract: Compositions and methods for treating solid tumors are provided. Intraperitoneal administration of sodium meta arsenite, alone or in combination with an anti-cancer agent, results in tumor necrosis and delayed tumor growth. A particularly effective treatment for colon and rectal cancer is a combination of sodium meta arsenite administered intraperitoneally and irinotecan.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 4, 2012
    Inventor: Young Joo MIN